
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing substantial growth in its Auryon product line, which is successfully expanding its customer base in both the Office-Based Lab (OBL) and hospital settings, positively impacting average selling prices (ASP). The company's focus on improving gross margins through manufacturing initiatives, projected to complete by January 2026, is expected to enhance profitability, supported by a favorable revenue mix with higher contributions from its Med-Tech segment. Management's confidence in sustained growth driven by increasing customer acquisition, utilization in existing accounts, and effective pricing strategies further bolsters the positive outlook for the company's financial performance.
Bears say
AngioDynamics Inc is facing significant challenges due to anticipated tariff headwinds amounting to $4 million to $6 million, which could impact its revenue projections. Additionally, the company expects to encounter pressures on its inventory in the second half of 2026 due to rising raw material costs, further complicating its cost structure. Furthermore, despite recent growth in capital sales, which are indicative of future demand for disposables, the strong performance of NanoKnife disposables in the first quarter of 2026 raises concerns about sustainability in the broader context of financial pressures.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares